Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Chen, Guochun ^a,b   Chen, Huihui ^a   Wang, Chang ^a,b   Peng, Youming ^a,b   Sun, Lin ^a,b   Liu, Hong ^a,b   Liu, Fuyou ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARISTOLOCHIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; ARISTOLOCHIC ACID I; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, MOUSE; MUTAGENIC AGENT; TARGET OF RAPAMYCIN KINASE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL STIMULATION; CONTROLLED STUDY; ENDOTHELIUM CELL; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FEMALE; FIBROGENESIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTERSTITIAL MACROPHAGE; KIDNEY EPITHELIUM; KIDNEY FIBROSIS; MACROPHAGE; METABOLIC INHIBITION; MOUSE; MYOFIBROBLAST; NEUTROPHIL; NONHUMAN; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION; URETER OBSTRUCTION; ANIMAL; C57BL MOUSE; CELL LINE; CELL PROLIFERATION; CELL STRAIN 3T3; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; FIBROBLAST; FIBROSIS; IMMUNOLOGY; INTESTINE; KIDNEY DISEASE; METABOLISM; PATHOLOGY;

MAMMALIA; MUS;

ANIMALS; ARISTOLOCHIC ACIDS; CELL LINE; CELL PROLIFERATION; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBROSIS; IMMUNOSUPPRESSIVE AGENTS; INTESTINES; KIDNEY DISEASES; MACROPHAGES; MICE; MICE, INBRED C57BL; MUTAGENS; MYOFIBROBLASTS; NIH 3T3 CELLS; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84859060783     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033626     Document Type: Article

References (38)

1. Huber TB, Walz G, Kuehn EW, (2011) mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression. Kidney Int 79: 502-511.
2. Wu MJ, Wen MC, Chiu YT, Chiou YY, Shu KH, et al. (2006) Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int 69: 2029-2036.
3. Lieberthal W, Levine JS, (2009) The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol 20: 2493-2502.
4. Lock HR, Sacks SH, Robson MG, (2007) Rapamycin at subimmunosuppressive levels inhibits mesangial cell proliferation and extracellular matrix production. Am J Physiol Renal Physiol 292: F76-81.
5. Bonegio RG, Fuhro R, Wang Z, Valeri CR, Andry C, et al. (2005) Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 16: 2063-2072.
6. Schaefer L, Tsalastra W, Babelova A, Baliova M, Minnerup J, et al. (2007) Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and Mammalian target of rapamycin. Am J Pathol 170: 301-315.
7. Kramer S, Wang-Rosenke Y, Scholl V, Binder E, Loof T, et al. (2008) Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat. Am J Physiol Renal Physiol 294: F440-449.
8. Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV, (2010) Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 16: 535-543, 531p following 143.
9. Vinuesa E, Hotter G, Jung M, Herrero-Fresneda I, Torras J, et al. (2008) Macrophage involvement in the kidney repair phase after ischaemia/reperfusion injury. J Pathol 214: 104-113.
10. Strutz F, Zeisberg M, (2006) Renal fibroblasts and myofibroblasts in chronic kidney disease. J Am Soc Nephrol 17: 2992-2998.
11. Hay N, Sonenberg N, (2004) Upstream and downstream of mTOR. Genes Dev 18: 1926-1945.
12. Lee DF, Hung MC, (2007) All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle 6: 3011-3014.
13. Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, et al. (2007) IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130: 440-455.
14. Shegogue D, Trojanowska M, (2004) Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway. J Biol Chem 279: 23166-23175.
15. Wang S, Wilkes MC, Leof EB, Hirschberg R, (2010) Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis. Am J Physiol Renal Physiol 298: F142-149.
16. Winbanks CE, Grimwood L, Gasser A, Darby IA, Hewitson TD, et al. (2007) Role of the phosphatidylinositol 3-kinase and mTOR pathways in the regulation of renal fibroblast function and differentiation. Int J Biochem Cell Biol 39: 206-219.
17. Guo G, Morrissey J, McCracken R, Tolley T, Klahr S, (1999) Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy. Am J Physiol 277: F766-772.
18. Ichimura T, Asseldonk EJ, Humphreys BD, Gunaratnam L, Duffield JS, et al. (2008) Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest 118: 1657-1668.
19. Liu FY, Li XZ, Peng YM, Liu H, Liu YH, (2008) Arkadia regulates TGF-beta signaling during renal tubular epithelial to mesenchymal cell transition. Kidney Int 73: 588-594.
20. Harris RC, Neilson EG, (2006) Toward a unified theory of renal progression. Annu Rev Med 57: 365-380.
21. McMahon G, Weir MR, Li XC, Mandelbrot DA, (2011) The evolving role of mTOR inhibition in transplantation tolerance. J Am Soc Nephrol 22: 408-415.
22. Ferrer IR, Araki K, Ford ML, (2011) Paradoxical aspects of rapamycin immunobiology in transplantation. Am J Transplant 11: 654-659.
23. Anders HJ, Ryu M, (2011) Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int.
24. Liu Y, (2011) Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 7: 684-696.
25. Yang L, Humphreys BD, Bonventre JV, (2011) Pathophysiology of acute kidney injury to chronic kidney disease: maladaptive repair. Contrib Nephrol 174: 149-155.
26. Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, et al. (1998) Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 273: 4135-4142.
27. Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV, (2006) Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 290: F517-529.
28. Pozdzik AA, Salmon IJ, Debelle FD, Decaestecker C, Van den Branden C, et al. (2008) Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation. Kidney Int 73: 595-607.
29. Zhou L, Fu P, Huang XR, Liu F, Chung AC, et al. (2010) Mechanism of chronic aristolochic acid nephropathy: role of Smad3. Am J Physiol Renal Physiol 298: F1006-1017.
30. Yang L, Li X, Wang H, (2007) Possible mechanisms explaining the tendency towards interstitial fibrosis in aristolochic acid-induced acute tubular necrosis. Nephrol Dial Transplant 22: 445-456.
31. Lieberthal W, Fuhro R, Andry C, Patel V, Levine JS, (2006) Rapamycin delays but does not prevent recovery from acute renal failure: role of acquired tubular resistance. Transplantation 82: 17-22.
32. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, et al. (2006) The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 103: 5466-5471.
33. Shillingford JM, Piontek KB, Germino GG, Weimbs T, (2010) Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol 21: 489-497.
34. Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, et al. (2006) Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 17: 1395-1404.
35. Chen JK, Chen J, Thomas G, Kozma SC, Harris RC, (2009) S6 kinase 1 knockout inhibits uninephrectomy- or diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 297: F585-593.
36. Diekmann F, Rovira J, Carreras J, Arellano EM, Banon-Maneus E, et al. (2007) Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass. J Am Soc Nephrol 18: 2653-2660.
37. Lieberthal W, Fuhro R, Andry CC, Rennke H, Abernathy VE, et al. (2001) Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 281: F693-706.
38. Fogo AB, (2011) The targeted podocyte. J Clin Invest 121: 2142-2145.